Please ensure Javascript is enabled for purposes of website accessibility

Diabetes drugs: the next weight loss craze?

  • Tweet
  • Share on LinkedIn
  • Share via email
  • Print
  • Download

July 2023

Celebrity use has raised the profile of the latest diabetes drugs but this may not be the fad it seems. Helping obese patients get their condition under control could save the US healthcare system billions of dollars. With multiple diabetes drugs showing weight loss benefits, Newton healthcare analyst Matthew Jenkin says for the first time there may be an anti-obesity agent that is not just a trend.


  • Obesity costs the US healthcare system US$173bn annually1 
  • Global anti-obesity drug market is expected to reach US$5,407.1m in 20262 
  • Patients have lost as much as 21% body weight while taking some newer diabetes medications3

From Hollywood elite to social media influencers, medications initially intended to ameliorate symptoms associated with type 2 diabetes is gaining popularity among those trying to lose their love handles.4 Now, the popular semaglutide medications are in short supply.5

Diabetes and weight loss connection

In the last several years, a few companies have developed glucagon-like peptide 1 (GLP-1) medicines to treat diabetes. More recently, one company in particular added a second mechanism. The original goal for these medicines was to treat diabetes, but they have also been shown to give hope to those battling obesity.

The diabetes medication is taken as a weekly injection that patients administer themselves with a pen-like device. These drugs help in both lowering blood pressure and weight loss, making them potentially a real game changer, according to Jenkin.

“With the early drugs, patients would lose anywhere between 5 and 7% of their body weight over the course of 18 months,” says Jenkin. “In one case with the newer drugs, a significant portion of the patients got to healthy blood sugar levels and lost as much as 21% of their body weight at 18 months.”

The medication isn’t just a fad. “The patients that are on drugs are not plateauing,” notes Jenkin. They are not losing lean body mass, they are actually losing fat.”

Financial burden of obesity

More than one billion people globally are obese – and that number is growing.6 Being pudgy is more than an issue of vanity as the condition is associated with a myriad of ailments including type 2 diabetes, cardiovascular disease and hypertension.

“If you can materially bring down people’s weight and at the same time control their diabetes, think about all the complications, like heart attacks, that you’ll save the healthcare system in money down the stream,” says Jenkin. “The costs an obese, diabetic patient presents to the healthcare system is enormous when they get to the point they are having cardiovascular and other problems.”

Treating obesity as a metabolic disease

In the US alone, obesity costs the healthcare system US$173bn a year, which could help make anti-obesity drugs a major category in the pharmaceutical sector. In fact, the global anti-obesity drug market is expected to reach US$5,407.1m by 2026.

Chart of average annual health expenditure due to

“What they (researchers) realized is the blood sugar lowering of these agents versus the old oral ones are two and three times as good at lowering blood sugar, but what they also do is increase satiety,” says Jenkin. “Not only were these patients lowering their blood sugar in a pronounced way, but they were losing a fair bit of body weight.”

This change is notable from previous diabetes drugs where weight loss wasn’t as significant.

Historically obesity has often been perceived as a lifestyle choice, but views of the condition and how to manage it are changing. Obesity has been categorized as a chronic disease by the American Medical Association since 2013 and with that distinction comes potential for more insurers to cover treatments.7

“Overtime, armed with these new medicines, we expect physicians to treat obesity as a disease versus a behavioral choice,” says Jenkin. “If the biopharma companies that make these medicines can prove the weight loss drives improved outcomes to patients in the long run, like less heart attacks, hospitalizations and deaths, then insurance companies and governments will cover a large portion of the patient expenses.”

1 Centers for Disease Control and Prevention. Overweight and obesity. July 2022.

2 Visiongain Reports, LTD. Global Anti-Obesity Drugs Market is projected to reach a market value of US$11,079.1 Million by 2031. August 2022.

3 New England Journal of Medicine. Jastreboff, Ania M., M.D., Ph.D., et al, Tirzepatide once weekly for the treatment of obesity. July 2022.

4 People. Stars who’ve spoken about Ozempic – and what they’ve said. May 2023.

5 American Society of Health-System Pharmacists. May 2023.

6 World Health Organization. Press release: World obesity day 2022 – Accelerating action to stop obesity. March 2022.

7 The New York Times. AMA recognizes obesity as a disease. June 2013.



This material should not be considered as investment advice or a recommendation of any investment manager or account arrangement, and should not serve as a primary basis for investment decisions. Any statements and opinions expressed are those of the author as at the date of publication, are subject to change as economic and market conditions dictate, and do not necessarily represent the views of BNY Mellon or any of its affiliates. The information has been provided as a general market commentary only and does not constitute legal, tax, accounting, other professional counsel or investment advice, is not predictive of future performance, and should not be construed as an offer to sell or a solicitation to buy any security or make an offer where otherwise unlawful. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. BNY Mellon and its affiliates are not responsible for any subsequent investment advice given based on the information supplied. This is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. This information may contain projections or other forward-looking statements regarding future events, targets or expectations, and is only current as of the date indicated. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. References to specific securities, asset classes and financial markets are for illustrative purposes only and are not intended to be and should not be interpreted as recommendations. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which BNY Mellon believed to be reliable, but BNY Mellon makes no representation to its accuracy and completeness. BNY Mellon accepts no liability for loss arising from use of this material.

All investments involve risk including loss of principal.

Not for distribution to, or use by, any person or entity in any jurisdiction or country in which such distribution or use would be contrary to local law or regulation. This information may not be distributed or used for the purpose of offers or solicitations in any jurisdiction or in any circumstances in which such offers or solicitations are unlawful or not authorized, or where there would be, by virtue of such distribution, new or additional registration requirements. Persons into whose possession this information comes are required to inform themselves about and to observe any restrictions that apply to the distribution of this information in their jurisdiction.

Issuing entities

This material is only for distribution in those countries and to those recipients listed, subject to the noted conditions and limitations: For Institutional, Professional, Qualified Investors and Qualified Clients. For General Public Distribution in the U.S. Only.United States: by BNY Mellon Securities Corporation (BNYMSC), 240 Greenwich Street, New York, NY 10286. BNYMSC, a registered broker-dealer and FINRA member, and subsidiary of BNY Mellon, has entered into agreements to offer securities in the U.S. on behalf of certain BNY Mellon Investment Management firms. • Europe (excluding Switzerland): BNY Mellon Fund Management (Luxembourg) S.A., 2-4 Rue EugèneRuppertL-2453 Luxembourg. • UK, Africa and Latin America (ex-Brazil): BNY Mellon Investment Management EMEA Limited, BNY Mellon Centre, 160 Queen Victoria Street, London EC4V 4LA. Registered in England No. 1118580. Authorised and regulated by the Financial Conduct Authority. • South Africa: BNY Mellon Investment Management EMEA Limited is an authorised financial services provider. • Switzerland: BNY Mellon Investments Switzerland GmbH, Bärengasse 29, CH-8001 Zürich, Switzerland. • Middle East: DIFC branch of The Bank of New York Mellon. Regulated by the Dubai Financial Services Authority. • Singapore: BNY Mellon Investment Management Singapore Pte. Limited Co. Reg. 201230427E. Regulated by the Monetary Authority of Singapore. • Hong Kong: BNY Mellon Investment Management Hong Kong Limited. Regulated by the Hong Kong Securities and Futures Commission. • Japan: BNY Mellon Investment Management Japan Limited. BNY Mellon Investment Management Japan Limited is a Financial Instruments Business Operator with license no 406 (Kinsho) at the Commissioner of Kanto Local Finance Bureau and is a Member of the Investment Trusts Association, Japan and Japan Investment Advisers Association and Type II Financial Instruments Firms Association. • Australia: BNY Mellon Investment Management Australia Ltd (ABN 56 102 482 815, AFS License No. 227865). Authorized and regulated by the Australian Securities & Investments Commission. • Brazil: ARX Investimentos Ltda., Av. Borges de Medeiros, 633, 4th floor, Rio de Janeiro, RJ, Brazil, CEP 22430-041. Authorized and regulated by the Brazilian Securities and Exchange Commission (CVM). • Canada: BNY Mellon Asset Management Canada Ltd. is registered in all provinces and territories of Canada as a Portfolio Manager and Exempt Market Dealer, and as a Commodity Trading Manager in Ontario. 


BNY Mellon Investment Management is one of the world’s leading investment management organizations, encompassing BNY Mellon’s affiliated investment management firms and global distribution companies. BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation and may also be used as a generic term to reference the corporation as a whole or its various subsidiaries generally. • Mellon Investments Corporation (MIC) is a registered investment advisor and subsidiary of The Bank of New York Mellon Corporation. MIC is composed of two divisions: Mellon, which specializes in index management, and Dreyfus, which specializes in cash management and short duration strategies. Dreyfus is also a division of BNY Mellon Investment Adviser, Inc. (BNYMIA), a registered investment adviser. • Insight Investments - Investment advisory services in North America are provided through two different investment advisers registered with the Securities and Exchange Commission (SEC) using the brand Insight Investment: Insight North America LLC (INA) and Insight Investment International Limited (IIIL). The North American investment advisers are associated with other global investment managers that also (individually and collectively) use the corporate brand Insight. Insight is a subsidiary of BNY Mellon. • Newton Investment Management - “Newton” and/or the “Newton Investment Management” brand refers to the following group of affiliated companies: Newton Investment Management Limited (NIM) and Newton Investment Management North America LLC (NIMNA). NIM is incorporated in the United Kingdom (Registered in England no. 1371973) and is authorized and regulated by the Financial Conduct Authority in the conduct of investment business. Both Newton firms are registered with the Securities and Exchange Commission (SEC) in the United States of America as an investment adviser under the Investment Advisers Act of 1940. Newton is a subsidiary of The Bank of New York Mellon Corporation. • ARX is the brand used to describe the Brazilian investment capabilities of BNY Mellon ARX Investimentos Ltda. ARX is a subsidiary of BNY Mellon. • Walter Scott & Partners Limited (Walter Scott) is an investment management firm authorized and regulated by the Financial Conduct Authority, and a subsidiary of BNY Mellon. • Siguler Guff - BNY Mellon owns a 20% interest in Siguler Guff & Company, LP and certain related entities (including Siguler Guff Advisers LLC). • BNY Mellon Investor Solutions, LLC is an investment adviser registered as such with the U.S. Securities and Exchange Commission (“SEC”) pursuant to the Investment Advisers Act of 1940, as amended. BNY Mellon Investor Solutions, LLC is a subsidiary of The Bank of New York Mellon Corporation. 

No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission. All information contained herein is proprietary and is protected under copyright law.




GU-444 – 29 December 2023